drugset / Trial / NCT07588646

Study To Investigate The Potential DDI Between HEC585 And Pirfenidone/Nintedanib In Healthy Subjects

NCT07588646

Phase 1 Completed 33 enrolled Sunshine Lake Pharma Co., Ltd.
Non-randomizedSequentialOpen-labelTreatment

Summary

A single-center, open-label study designed to assess the drug-drug interaction of HEC585 and pirfenidone in healthy male and female subjects. A single-center, open-label study designed to assess the drug-drug interaction of HEC585 and nintedanib in healthy male subjects.

Timeline

Start
2021-06-29
Primary completion
2021-11-30
Completion
2021-11-30

Drugs

EvaluationDrugModalityDoseRoute
Subject HEC585 Small molecule
Subject Nintedanib Small molecule
Subject Pirfenidone Small molecule